Tafinlar (Dabrafenib Mesylate) Patent Expiration, LOE Window & CMS Spending

Tafinlar (Dabrafenib Mesylate) by Novartis: FDA Orange Book core substance LOE 2031-04-15 (last listed 2034-02-28), 0 AB generics, $220.2M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN202806 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-04-15
Last Listed Patent or Exclusivity Date2034-02-28
Orange Book Patents (*PED Extensions)12 patents (6 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$220.2M
2024 Medicare Part D Spend$173.9M
2024 Medicaid Spend$46.3M
Reported Wholesale Price Change (CA SB 17)10 WAC filings (max 26.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.